Education
About Us
Working with TipRanks
Follow Us
Hansa Biopharma AB (SE:HNSA)
:HNSA
HNSA Stock Chart & Stats
Day’s Range― - ―
52-Week Rangekr21.64 - kr57.30
Previous CloseN/A
Volume97.73K
Average Volume (3M)206.18K
Market Cap
kr1.53B
Enterprise Valuekr3.33B
Total Cash (Recent Filing)kr339.93M
Total Debt (Recent Filing)kr15.23M
Price to Earnings (P/E)―
Beta-0.11
Next Earnings
Apr 17, 2025EPS Estimate
-2.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-13.06
Shares Outstanding67,814,240
10 Day Avg. Volume112,176
30 Day Avg. Volume206,180
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
kr143.00Price Target Upside535.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
Bulls Say, Bears Say
Bulls Say
Clinical Trial ProgressThe completion of patient enrollment in the pivotal Phase 3 trial for anti-GBM disease is ahead of schedule, highlighting the company's progress and the unmet needs in the autoimmune space.
Reimbursement ExpansionReimbursement is now available in major cities such as Barcelona and Madrid, which should increase patient access.
Sales PerformanceHansa recorded its highest sales performance with a total revenue of SEK78.4M for 3Q 2024, of which SEK69.5M was attributed to Idefirix sales, despite this being a seasonally slow quarter.
Bears Say
Market CompetitionManagement believes HNSA-5487 stays in a competitive position, as it cleaves IgG 1, 2, 3, and 4 with similar efficiency, compared with Biohaven's IgG degrader, which spares IgG3.
Sales DeclineIdefirix's 4Q sales disappointed with product sales of SEK25.6M, representing a 41% YoY and a 36% QoQ decrease, which was below estimate.
---
Options Prices
Currently, No data available
---
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
― Other Institutional Investors
99.75% Public Companies and
Individual Investors
HNSA FAQ
What was Hansa Biopharma AB’s price range in the past 12 months?
Hansa Biopharma AB lowest stock price was kr21.64 and its highest was kr57.30 in the past 12 months.
What is Hansa Biopharma AB’s market cap?
Hansa Biopharma AB’s market cap is kr1.53B.
When is Hansa Biopharma AB’s upcoming earnings report date?
Hansa Biopharma AB’s upcoming earnings report date is Apr 17, 2025 which is in 17 days.
How were Hansa Biopharma AB’s earnings last quarter?
Hansa Biopharma AB released its earnings results on Feb 06, 2025. The company reported -kr4.08 earnings per share for the quarter, missing the consensus estimate of -kr1.981 by -kr2.099.
Is Hansa Biopharma AB overvalued?
According to Wall Street analysts Hansa Biopharma AB’s price is currently Undervalued.
Does Hansa Biopharma AB pay dividends?
Hansa Biopharma AB does not currently pay dividends.
What is Hansa Biopharma AB’s EPS estimate?
Hansa Biopharma AB’s EPS estimate is -2.61.
How many shares outstanding does Hansa Biopharma AB have?
Hansa Biopharma AB has 67,814,240 shares outstanding.
What happened to Hansa Biopharma AB’s price movement after its last earnings report?
Hansa Biopharma AB reported an EPS of -kr4.08 in its last earnings report, missing expectations of -kr1.981. Following the earnings report the stock price went down -19.393%.
Which hedge fund is a major shareholder of Hansa Biopharma AB?
Currently, no hedge funds are holding shares in SE:HNSA
---
Company Description
Hansa Biopharma AB
Hansa Biopharma AB (publ), a biopharmaceutical company, develops immunomodulatory treatments for enabling transplants and rare immunoglobulin G (IgG)-mediated autoimmune conditions, gene therapy, and cancer using its proprietary enzyme technology platform. The company's lead drug candidate is Imlifidase, an antibody cleaving enzyme therapy that is in phase 3 clinical trial for use in sensitized kidney transplantations patients, as well as for anti-GBM antibody disease; and phase 2 clinical trial for antibody-mediated kidney transplant rejection and Guillain Barré syndrome. It is also developing Novel immunoglobulin cleaving enzymes for Repeat dosing (NiceR) for the treatment of autoimmune diseases, transplantation, and oncology; and Enzyme based antibody Enhancement (EnzE), which is cancer immunotherapy. The company has a preclinical research collaboration agreement with argenx BV to evaluate the therapeutic potential of combining the two companies' IgG-modulating technologies. Hansa Biopharma AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.
---
HNSA Stock 12 Month Forecast
Average Price Target
kr143.00
▲(535.56% Upside)
Technical Analysis
Best Analysts Covering HNSA
1 Year
1 Year Success Rate
2/22 ratings generated profit
1 Year Average Return
-24.75%
reiterated a buy rating 2 months ago
Copying Douglas Tsao's trades and holding each position for 1 Year would result in 9.09% of your transactions generating a profit, with an average return of -24.75% per trade.
---